Analysis of a panel-based pharmacogenomics testing program among members of a commercial and Medicare client of a pharmacy benefits manager.
J Manag Care Spec Pharm
; 28(4): 485-490, 2022 Apr.
Article
em En
| MEDLINE
| ID: mdl-35332788
ABSTRACT
BACKGROUND:
Although the field of pharmacogenomics (PGx) has existed for decades, use of pharmacogenomic information by providers to optimize medication therapy for patients has had relatively slow adoption. There are many factors that have contributed to the slow adoption of PGx testing, but it is partially due to a lack of coverage by payers. If PGx testing is covered by payers, frequently only testing of a specific gene is covered, rather than a panel of many genes. As a result, little is known about how coverage of a panel-based PGx test will affect a member's medication therapy.OBJECTIVES:
To determine how giving providers specific medication optimization recommendations, based on results of a panel-based PGx test, impacted members' medication regimens.METHODS:
Pharmacy claims data were retrospectively reviewed for this exploratory study. Members who participated in PGx testing were in the intervention group and members who chose not to participate in the PGx testing, but who were eligible to participate, were in the control group. PGx test results, including suggested medication changes, were mailed to providers. To determine if providers adopted the suggested medication changes, pharmacy claims data were analyzed retrospectively for the 4-month period preceding and following the date from which recommendations were provided to prescribers.RESULTS:
Of the 101 members included in the analysis, 50 were in the intervention group and 51 were in the control group. In the intervention group, members were taking in a total of 352 medications; 165 of the medications had PGx guidance. Based on the PGx test results, 62 of these medications (37.6%) had recommendations. Of members who received PGx testing, 76% had at least 1 recommended change. When pharmacist recommendations were made, a change was made to the medication 27% of the time. There was a statistically significant difference between the number of medication changes in the PGx group and the control group (P = 0.024).CONCLUSIONS:
Recommendations based on PGx testing can lead to changes in medications and an optimized medication regimen for members. DISCLOSURES The authors have no conflicts to disclose that may present a potential conflict of interest.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmácia
/
Assistência Farmacêutica
Tipo de estudo:
Guideline
/
Observational_studies
Limite:
Aged
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Manag Care Spec Pharm
Ano de publicação:
2022
Tipo de documento:
Article